Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1

Status

Completed 9Recruiting 6Terminated 5Active not recruiting 5Unknown 2Suspended 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 174Other hematologic neoplasm 124Breast 61Plasma cell 37Myeloid 31Gastrointestinal 30CNS 27Sarcoma 24Dermatologic 23Other solid neoplasm 18Gynecologic 18Thoracic 16Genitourinary 12Classical hematology 11Tumor-Agnostic 6Head & Neck 6NET 3Endocrine 3Other neoplasm 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Carcinoma 2

Interventions

pembrolizumab 25Specimen Handling 17Blood Specimen Collection 17Biopsy 16Magnetic Resonance Spectroscopy 15atezolizumab 11Surveys and Questionnaires 11Radiosurgery 9Bevacizumab 9Paclitaxel 8Fluorouracil 8Standard of Care 7Radiotherapy 7Nivolumab 7Irinotecan 7Gemcitabine 7Cisplatin 7Carboplatin 7olaparib 6durvalumab 6Palliative Care 6Oxaliplatin 6Leucovorin 6Cyclophosphamide 6Capecitabine 6alectinib 5abemaciclib 5Trastuzumab 5Interviews as Topic 5Exercise 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Cyclophosphamide × Tumor-Agnostic × Clear all
NCT05999994 2026-03-27

CAMPFIRE

Eli Lilly and Company

Phase 2 Recruiting
105 enrolled
Tumor-Agnostic

Neoplasms

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

NCT06043713 2025-12-19

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations

Fred Hutchinson Cancer Center

Phase 1 Recruiting
24 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06415487 2025-07-01

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

Acepodia Biotech, Inc.

Phase 1 Recruiting
30 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05141474 2024-11-07

NEXTGENTIL-ACT

Vall d'Hebron Institute of Oncology

Phase EARLY_PHASE1 Recruiting
10 enrolled
Tumor-Agnostic

Carcinoma

NCT06013111 2024-02-21

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors

China Medical University, China

Phase 1 Recruiting
9 enrolled
Tumor-Agnostic

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡